PIK3CA mutation occurs in approximately 35% of HR-positive breast cancers, in about 20%-25% of HER2-overexpressing breast cancers, and with a lower frequency in triple-negative breast cancers10 (Table 1). This evidence concerns the gene ERBB2 and breast cancer.